nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0265	0.0406	CbGbCtD
Irbesartan—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0265	0.0406	CbGbCtD
Irbesartan—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0242	0.0369	CbGbCtD
Irbesartan—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0227	0.0347	CbGbCtD
Irbesartan—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0227	0.0347	CbGbCtD
Irbesartan—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0218	0.0333	CbGbCtD
Irbesartan—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0205	0.0314	CbGbCtD
Irbesartan—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0205	0.0313	CbGbCtD
Irbesartan—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0205	0.0313	CbGbCtD
Irbesartan—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0201	0.0307	CbGbCtD
Irbesartan—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0201	0.0307	CbGbCtD
Irbesartan—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0199	0.0304	CbGbCtD
Irbesartan—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0193	0.0295	CbGbCtD
Irbesartan—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0187	0.0286	CbGbCtD
Irbesartan—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0187	0.0286	CbGbCtD
Irbesartan—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0185	0.0283	CbGbCtD
Irbesartan—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0185	0.0283	CbGbCtD
Irbesartan—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0172	0.0263	CbGbCtD
Irbesartan—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0169	0.0259	CbGbCtD
Irbesartan—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0169	0.0259	CbGbCtD
Irbesartan—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.016	0.0244	CbGbCtD
Irbesartan—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0156	0.0238	CbGbCtD
Irbesartan—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0155	0.0237	CbGbCtD
Irbesartan—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0146	0.0223	CbGbCtD
Irbesartan—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0142	0.0217	CbGbCtD
Irbesartan—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.014	0.0214	CbGbCtD
Irbesartan—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.014	0.0214	CbGbCtD
Irbesartan—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0134	0.0206	CbGbCtD
Irbesartan—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0128	0.0196	CbGbCtD
Irbesartan—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0128	0.0196	CbGbCtD
Irbesartan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0127	0.0193	CbGbCtD
Irbesartan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0119	0.0182	CbGbCtD
Irbesartan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0119	0.0182	CbGbCtD
Irbesartan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0164	CbGbCtD
Irbesartan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0164	CbGbCtD
Irbesartan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00929	0.0142	CbGbCtD
Irbesartan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00902	0.0138	CbGbCtD
Irbesartan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00815	0.0125	CbGbCtD
Irbesartan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00815	0.0125	CbGbCtD
Irbesartan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00782	0.012	CbGbCtD
Irbesartan—JUN—nerve—acquired immunodeficiency syndrome	0.00407	0.0747	CbGeAlD
Irbesartan—JUN—endothelium—acquired immunodeficiency syndrome	0.00347	0.0636	CbGeAlD
Irbesartan—AGTR1—endothelium—acquired immunodeficiency syndrome	0.00261	0.0479	CbGeAlD
Irbesartan—AGTR1—blood plasma—acquired immunodeficiency syndrome	0.00232	0.0425	CbGeAlD
Irbesartan—UGT1A3—digestive system—acquired immunodeficiency syndrome	0.00209	0.0384	CbGeAlD
Irbesartan—JUN—retina—acquired immunodeficiency syndrome	0.00169	0.0309	CbGeAlD
Irbesartan—JUN—skin of body—acquired immunodeficiency syndrome	0.00148	0.0272	CbGeAlD
Irbesartan—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00126	0.0231	CbGeAlD
Irbesartan—JUN—lymphoid tissue—acquired immunodeficiency syndrome	0.0012	0.022	CbGeAlD
Irbesartan—JUN—digestive system—acquired immunodeficiency syndrome	0.00118	0.0217	CbGeAlD
Irbesartan—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00118	0.0216	CbGeAlD
Irbesartan—PTGS1—endothelium—acquired immunodeficiency syndrome	0.00115	0.0211	CbGeAlD
Irbesartan—EDNRA—vagina—acquired immunodeficiency syndrome	0.00115	0.021	CbGeAlD
Irbesartan—JUN—blood—acquired immunodeficiency syndrome	0.00113	0.0207	CbGeAlD
Irbesartan—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00112	0.0205	CbGeAlD
Irbesartan—JUN—bone marrow—acquired immunodeficiency syndrome	0.00109	0.02	CbGeAlD
Irbesartan—JUN—spinal cord—acquired immunodeficiency syndrome	0.00109	0.0199	CbGeAlD
Irbesartan—EDNRA—lung—acquired immunodeficiency syndrome	0.00108	0.0199	CbGeAlD
Irbesartan—JUN—vagina—acquired immunodeficiency syndrome	0.00105	0.0192	CbGeAlD
Irbesartan—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.00102	0.0187	CbGeAlD
Irbesartan—JUN—lung—acquired immunodeficiency syndrome	0.000989	0.0181	CbGeAlD
Irbesartan—JUN—nervous system—acquired immunodeficiency syndrome	0.000916	0.0168	CbGeAlD
Irbesartan—AGTR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000903	0.0166	CbGeAlD
Irbesartan—JUN—central nervous system—acquired immunodeficiency syndrome	0.000882	0.0162	CbGeAlD
Irbesartan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000852	0.0156	CbGeAlD
Irbesartan—AGTR1—blood—acquired immunodeficiency syndrome	0.00085	0.0156	CbGeAlD
Irbesartan—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000838	0.0154	CbGeAlD
Irbesartan—AGTR1—vagina—acquired immunodeficiency syndrome	0.000788	0.0144	CbGeAlD
Irbesartan—EDNRA—brain—acquired immunodeficiency syndrome	0.000767	0.0141	CbGeAlD
Irbesartan—AGTR1—lung—acquired immunodeficiency syndrome	0.000745	0.0137	CbGeAlD
Irbesartan—EDNRA—lymph node—acquired immunodeficiency syndrome	0.000741	0.0136	CbGeAlD
Irbesartan—JUN—brain—acquired immunodeficiency syndrome	0.0007	0.0128	CbGeAlD
Irbesartan—AGTR1—nervous system—acquired immunodeficiency syndrome	0.00069	0.0127	CbGeAlD
Irbesartan—JUN—lymph node—acquired immunodeficiency syndrome	0.000676	0.0124	CbGeAlD
Irbesartan—AGTR1—central nervous system—acquired immunodeficiency syndrome	0.000664	0.0122	CbGeAlD
Irbesartan—Valsartan—ALB—acquired immunodeficiency syndrome	0.000616	0.672	CrCbGaD
Irbesartan—AGTR1—brain—acquired immunodeficiency syndrome	0.000527	0.00967	CbGeAlD
Irbesartan—AGTR1—lymph node—acquired immunodeficiency syndrome	0.000509	0.00935	CbGeAlD
Irbesartan—PTGS1—skin of body—acquired immunodeficiency syndrome	0.00049	0.00899	CbGeAlD
Irbesartan—CYP2C8—blood—acquired immunodeficiency syndrome	0.000461	0.00845	CbGeAlD
Irbesartan—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000452	0.0083	CbGeAlD
Irbesartan—CYP1A2—blood—acquired immunodeficiency syndrome	0.000431	0.00791	CbGeAlD
Irbesartan—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000429	0.00788	CbGeAlD
Irbesartan—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000427	0.00783	CbGeAlD
Irbesartan—CYP2C9—blood—acquired immunodeficiency syndrome	0.000409	0.00751	CbGeAlD
Irbesartan—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000392	0.00719	CbGeAlD
Irbesartan—CYP1A2—lung—acquired immunodeficiency syndrome	0.000378	0.00693	CbGeAlD
Irbesartan—PTGS1—blood—acquired immunodeficiency syndrome	0.000374	0.00685	CbGeAlD
Irbesartan—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.00036	0.0066	CbGeAlD
Irbesartan—PTGS1—vagina—acquired immunodeficiency syndrome	0.000346	0.00635	CbGeAlD
Irbesartan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000327	0.00601	CbGeAlD
Irbesartan—PTGS1—lung—acquired immunodeficiency syndrome	0.000327	0.00601	CbGeAlD
Irbesartan—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000322	0.00591	CbGeAlD
Irbesartan—CYP3A4—blood—acquired immunodeficiency syndrome	0.000312	0.00572	CbGeAlD
Irbesartan—CYP2D6—blood—acquired immunodeficiency syndrome	0.000307	0.00563	CbGeAlD
Irbesartan—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000303	0.00556	CbGeAlD
Irbesartan—Losartan—ALB—acquired immunodeficiency syndrome	0.000301	0.328	CrCbGaD
Irbesartan—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000292	0.00536	CbGeAlD
Irbesartan—CYP2C8—brain—acquired immunodeficiency syndrome	0.000286	0.00524	CbGeAlD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000257	0.00435	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000254	0.00431	CbGpPWpGaD
Irbesartan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000253	0.00465	CbGeAlD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000251	0.00425	CbGpPWpGaD
Irbesartan—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000249	0.00457	CbGeAlD
Irbesartan—JUN—IL-5 Signaling Pathway—IL2—acquired immunodeficiency syndrome	0.000249	0.00422	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000246	0.00418	CbGpPWpGaD
Irbesartan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000244	0.00447	CbGeAlD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000243	0.00412	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000242	0.0041	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000242	0.0041	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000241	0.00409	CbGpPWpGaD
Irbesartan—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00024	0.0044	CbGeAlD
Irbesartan—JUN—IL-2 Signaling Pathway—IL2—acquired immunodeficiency syndrome	0.00024	0.00406	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000235	0.00399	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000235	0.00398	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	0.000234	0.00397	CbGpPWpGaD
Irbesartan—PTGS1—brain—acquired immunodeficiency syndrome	0.000232	0.00425	CbGeAlD
Irbesartan—PTGS1—Overview of nanoparticle effects—TNF—acquired immunodeficiency syndrome	0.00023	0.00389	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—CCL5—acquired immunodeficiency syndrome	0.000226	0.00384	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000225	0.00382	CbGpPWpGaD
Irbesartan—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000224	0.00411	CbGeAlD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000223	0.00378	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IFNA1—acquired immunodeficiency syndrome	0.000222	0.00377	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—IFNG—acquired immunodeficiency syndrome	0.00022	0.00374	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.00022	0.00374	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00022	0.00373	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.000218	0.00369	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000213	0.00361	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000211	0.00358	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	0.000208	0.00353	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000207	0.00351	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000207	0.00351	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—IFNG—acquired immunodeficiency syndrome	0.000205	0.00348	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	0.000203	0.00344	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000202	0.00342	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000201	0.00341	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000199	0.00338	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000196	0.00332	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	0.000193	0.00328	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000191	0.00324	CbGpPWpGaD
Irbesartan—CYP2D6—brain—acquired immunodeficiency syndrome	0.000191	0.00349	CbGeAlD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000189	0.00321	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IFNG—acquired immunodeficiency syndrome	0.000188	0.00318	CbGpPWpGaD
Irbesartan—PTGS1—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.000185	0.00314	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000185	0.00314	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000184	0.00312	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	0.000183	0.00311	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IFNG—acquired immunodeficiency syndrome	0.000179	0.00304	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—CCL5—acquired immunodeficiency syndrome	0.000177	0.00299	CbGpPWpGaD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—TNF—acquired immunodeficiency syndrome	0.000174	0.00296	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000174	0.00296	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000173	0.00293	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000168	0.00284	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	0.000167	0.00283	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000166	0.00281	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000165	0.00281	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	0.000163	0.00276	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000162	0.00275	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000162	0.00275	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000162	0.00275	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.00016	0.00272	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL2—acquired immunodeficiency syndrome	0.000159	0.0027	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IFNG—acquired immunodeficiency syndrome	0.000158	0.00268	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000158	0.00267	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000158	0.00267	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000157	0.00267	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—acquired immunodeficiency syndrome	0.000156	0.00264	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000154	0.00261	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	0.000152	0.00257	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00015	0.00254	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000145	0.00246	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TNF—acquired immunodeficiency syndrome	0.000143	0.00242	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000142	0.0024	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000141	0.0024	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	0.000141	0.00239	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000141	0.00239	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL2—acquired immunodeficiency syndrome	0.00014	0.00238	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000139	0.00236	CbGpPWpGaD
Irbesartan—JUN—FCERI mediated MAPK activation—IL6—acquired immunodeficiency syndrome	0.000138	0.00234	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000131	0.00223	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00013	0.0022	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	0.00013	0.0022	CbGpPWpGaD
Irbesartan—JUN—IL6-mediated signaling events—IL6—acquired immunodeficiency syndrome	0.000129	0.00218	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000125	0.00212	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000124	0.0021	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000124	0.0021	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000124	0.00209	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.000123	0.00208	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	0.000122	0.00206	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000121	0.00205	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00012	0.00203	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000118	0.002	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TAT—acquired immunodeficiency syndrome	0.000116	0.00197	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.000114	0.00193	CbGpPWpGaD
Irbesartan—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000112	0.000486	CcSEcCtD
Irbesartan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000112	0.000486	CcSEcCtD
Irbesartan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000485	CcSEcCtD
Irbesartan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000485	CcSEcCtD
Irbesartan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000485	CcSEcCtD
Irbesartan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000485	CcSEcCtD
Irbesartan—JUN—MAP kinase activation in TLR cascade—IL6—acquired immunodeficiency syndrome	0.000112	0.0019	CbGpPWpGaD
Irbesartan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000112	0.000483	CcSEcCtD
Irbesartan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000483	CcSEcCtD
Irbesartan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000483	CcSEcCtD
Irbesartan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000482	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000481	CcSEcCtD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000111	0.00189	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000111	0.00048	CcSEcCtD
Irbesartan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000111	0.000479	CcSEcCtD
Irbesartan—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000479	CcSEcCtD
Irbesartan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000111	0.000479	CcSEcCtD
Irbesartan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000479	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000478	CcSEcCtD
Irbesartan—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000478	CcSEcCtD
Irbesartan—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000478	CcSEcCtD
Irbesartan—Pain—Indinavir—acquired immunodeficiency syndrome	0.00011	0.000475	CcSEcCtD
Irbesartan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00011	0.000475	CcSEcCtD
Irbesartan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00011	0.000475	CcSEcCtD
Irbesartan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000474	CcSEcCtD
Irbesartan—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000473	CcSEcCtD
Irbesartan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000109	0.000472	CcSEcCtD
Irbesartan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000109	0.000472	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000109	0.00185	CbGpPWpGaD
Irbesartan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000109	0.000472	CcSEcCtD
Irbesartan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000472	CcSEcCtD
Irbesartan—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000471	CcSEcCtD
Irbesartan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000109	0.00047	CcSEcCtD
Irbesartan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000109	0.00047	CcSEcCtD
Irbesartan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.00047	CcSEcCtD
Irbesartan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000109	0.00047	CcSEcCtD
Irbesartan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000469	CcSEcCtD
Irbesartan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000468	CcSEcCtD
Irbesartan—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000468	CcSEcCtD
Irbesartan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000467	CcSEcCtD
Irbesartan—EDNRA—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000108	0.00183	CbGpPWpGaD
Irbesartan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000467	CcSEcCtD
Irbesartan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000467	CcSEcCtD
Irbesartan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000467	CcSEcCtD
Irbesartan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000465	CcSEcCtD
Irbesartan—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000465	CcSEcCtD
Irbesartan—JUN—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	0.000107	0.00182	CbGpPWpGaD
Irbesartan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000107	0.000463	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000463	CcSEcCtD
Irbesartan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000462	CcSEcCtD
Irbesartan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000461	CcSEcCtD
Irbesartan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000459	CcSEcCtD
Irbesartan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000458	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000458	CcSEcCtD
Irbesartan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000457	CcSEcCtD
Irbesartan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000456	CcSEcCtD
Irbesartan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000456	CcSEcCtD
Irbesartan—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000456	CcSEcCtD
Irbesartan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000106	0.000456	CcSEcCtD
Irbesartan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000456	CcSEcCtD
Irbesartan—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000455	CcSEcCtD
Irbesartan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000105	0.000455	CcSEcCtD
Irbesartan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000454	CcSEcCtD
Irbesartan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000453	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000453	CcSEcCtD
Irbesartan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000105	0.000453	CcSEcCtD
Irbesartan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000453	CcSEcCtD
Irbesartan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000451	CcSEcCtD
Irbesartan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000451	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.000104	0.00177	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000449	CcSEcCtD
Irbesartan—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000449	CcSEcCtD
Irbesartan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000449	CcSEcCtD
Irbesartan—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.000449	CcSEcCtD
Irbesartan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.000449	CcSEcCtD
Irbesartan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000448	CcSEcCtD
Irbesartan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000104	0.000448	CcSEcCtD
Irbesartan—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000447	CcSEcCtD
Irbesartan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000447	CcSEcCtD
Irbesartan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000103	0.000446	CcSEcCtD
Irbesartan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000445	CcSEcCtD
Irbesartan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000445	CcSEcCtD
Irbesartan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000445	CcSEcCtD
Irbesartan—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000444	CcSEcCtD
Irbesartan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000444	CcSEcCtD
Irbesartan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000443	CcSEcCtD
Irbesartan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000442	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000442	CcSEcCtD
Irbesartan—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000102	0.000442	CcSEcCtD
Irbesartan—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.00044	CcSEcCtD
Irbesartan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.00044	CcSEcCtD
Irbesartan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000102	0.000439	CcSEcCtD
Irbesartan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000102	0.000439	CcSEcCtD
Irbesartan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000439	CcSEcCtD
Irbesartan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000439	CcSEcCtD
Irbesartan—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000438	CcSEcCtD
Irbesartan—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000101	0.000437	CcSEcCtD
Irbesartan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000437	CcSEcCtD
Irbesartan—JUN—Innate Immune System—MBL2—acquired immunodeficiency syndrome	0.000101	0.00171	CbGpPWpGaD
Irbesartan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000435	CcSEcCtD
Irbesartan—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000435	CcSEcCtD
Irbesartan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000434	CcSEcCtD
Irbesartan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000434	CcSEcCtD
Irbesartan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000434	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.000434	CcSEcCtD
Irbesartan—Rash—Stavudine—acquired immunodeficiency syndrome	0.0001	0.000434	CcSEcCtD
Irbesartan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.000433	CcSEcCtD
Irbesartan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.0001	0.000433	CcSEcCtD
Irbesartan—JUN—Apoptosis—TNF—acquired immunodeficiency syndrome	0.0001	0.0017	CbGpPWpGaD
Irbesartan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.000433	CcSEcCtD
Irbesartan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000432	CcSEcCtD
Irbesartan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.0001	0.000432	CcSEcCtD
Irbesartan—Headache—Stavudine—acquired immunodeficiency syndrome	9.97e-05	0.000431	CcSEcCtD
Irbesartan—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.97e-05	0.000431	CcSEcCtD
Irbesartan—Pain—Delavirdine—acquired immunodeficiency syndrome	9.94e-05	0.00043	CcSEcCtD
Irbesartan—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.94e-05	0.00043	CcSEcCtD
Irbesartan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.94e-05	0.000429	CcSEcCtD
Irbesartan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.92e-05	0.000429	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—AGPS—acquired immunodeficiency syndrome	9.88e-05	0.00168	CbGpPWpGaD
Irbesartan—Rash—Abacavir—acquired immunodeficiency syndrome	9.88e-05	0.000427	CcSEcCtD
Irbesartan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.87e-05	0.000427	CcSEcCtD
Irbesartan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	9.87e-05	0.000427	CcSEcCtD
Irbesartan—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.87e-05	0.000427	CcSEcCtD
Irbesartan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.86e-05	0.000426	CcSEcCtD
Irbesartan—Headache—Abacavir—acquired immunodeficiency syndrome	9.82e-05	0.000424	CcSEcCtD
Irbesartan—Infection—Lamivudine—acquired immunodeficiency syndrome	9.81e-05	0.000424	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.79e-05	0.000423	CcSEcCtD
Irbesartan—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.79e-05	0.000423	CcSEcCtD
Irbesartan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.78e-05	0.000423	CcSEcCtD
Irbesartan—Shock—Lamivudine—acquired immunodeficiency syndrome	9.71e-05	0.00042	CcSEcCtD
Irbesartan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.68e-05	0.000418	CcSEcCtD
Irbesartan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	9.67e-05	0.000418	CcSEcCtD
Irbesartan—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	9.67e-05	0.000418	CcSEcCtD
Irbesartan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	9.65e-05	0.000417	CcSEcCtD
Irbesartan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.65e-05	0.000417	CcSEcCtD
Irbesartan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.61e-05	0.000415	CcSEcCtD
Irbesartan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.61e-05	0.000415	CcSEcCtD
Irbesartan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.59e-05	0.000414	CcSEcCtD
Irbesartan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.58e-05	0.000414	CcSEcCtD
Irbesartan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	9.58e-05	0.000414	CcSEcCtD
Irbesartan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	9.56e-05	0.000413	CcSEcCtD
Irbesartan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	9.54e-05	0.000412	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.51e-05	0.00161	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.51e-05	0.000411	CcSEcCtD
Irbesartan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.48e-05	0.00041	CcSEcCtD
Irbesartan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9.47e-05	0.000409	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.47e-05	0.00161	CbGpPWpGaD
Irbesartan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.46e-05	0.000409	CcSEcCtD
Irbesartan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.46e-05	0.000409	CcSEcCtD
Irbesartan—Nausea—Stavudine—acquired immunodeficiency syndrome	9.45e-05	0.000408	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.43e-05	0.000407	CcSEcCtD
Irbesartan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	9.41e-05	0.000407	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.4e-05	0.00159	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL6—acquired immunodeficiency syndrome	9.36e-05	0.00159	CbGpPWpGaD
Irbesartan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.35e-05	0.000404	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—acquired immunodeficiency syndrome	9.32e-05	0.00158	CbGpPWpGaD
Irbesartan—Nausea—Abacavir—acquired immunodeficiency syndrome	9.31e-05	0.000402	CcSEcCtD
Irbesartan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	9.29e-05	0.000402	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.28e-05	0.000401	CcSEcCtD
Irbesartan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.27e-05	0.000401	CcSEcCtD
Irbesartan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	9.24e-05	0.000399	CcSEcCtD
Irbesartan—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.23e-05	0.000399	CcSEcCtD
Irbesartan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.23e-05	0.000399	CcSEcCtD
Irbesartan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	9.22e-05	0.000399	CcSEcCtD
Irbesartan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	9.2e-05	0.000398	CcSEcCtD
Irbesartan—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.19e-05	0.000397	CcSEcCtD
Irbesartan—Pain—Ritonavir—acquired immunodeficiency syndrome	9.19e-05	0.000397	CcSEcCtD
Irbesartan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.19e-05	0.000397	CcSEcCtD
Irbesartan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.19e-05	0.000397	CcSEcCtD
Irbesartan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.14e-05	0.000395	CcSEcCtD
Irbesartan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.11e-05	0.000394	CcSEcCtD
Irbesartan—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.1e-05	0.000393	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.09e-05	0.00154	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.09e-05	0.00154	CbGpPWpGaD
Irbesartan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.99e-05	0.000389	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.99e-05	0.000389	CcSEcCtD
Irbesartan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.95e-05	0.000387	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.93e-05	0.000386	CcSEcCtD
Irbesartan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.92e-05	0.000386	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.9e-05	0.00151	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.9e-05	0.00151	CbGpPWpGaD
Irbesartan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	8.86e-05	0.000383	CcSEcCtD
Irbesartan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	8.86e-05	0.000383	CcSEcCtD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	8.85e-05	0.0015	CbGpPWpGaD
Irbesartan—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.85e-05	0.000382	CcSEcCtD
Irbesartan—Pain—Saquinavir—acquired immunodeficiency syndrome	8.85e-05	0.000382	CcSEcCtD
Irbesartan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.8e-05	0.00038	CcSEcCtD
Irbesartan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.8e-05	0.00038	CcSEcCtD
Irbesartan—JUN—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.8e-05	0.00149	CbGpPWpGaD
Irbesartan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.79e-05	0.00038	CcSEcCtD
Irbesartan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.79e-05	0.00038	CcSEcCtD
Irbesartan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.78e-05	0.000379	CcSEcCtD
Irbesartan—Rash—Zidovudine—acquired immunodeficiency syndrome	8.72e-05	0.000377	CcSEcCtD
Irbesartan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.72e-05	0.000377	CcSEcCtD
Irbesartan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.71e-05	0.000376	CcSEcCtD
Irbesartan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.69e-05	0.000376	CcSEcCtD
Irbesartan—Headache—Zidovudine—acquired immunodeficiency syndrome	8.66e-05	0.000374	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.6e-05	0.00146	CbGpPWpGaD
Irbesartan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.6e-05	0.000372	CcSEcCtD
Irbesartan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.58e-05	0.000371	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	8.58e-05	0.00145	CbGpPWpGaD
Irbesartan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.57e-05	0.00037	CcSEcCtD
Irbesartan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.54e-05	0.000369	CcSEcCtD
Irbesartan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	8.53e-05	0.000369	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.52e-05	0.000368	CcSEcCtD
Irbesartan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.51e-05	0.000368	CcSEcCtD
Irbesartan—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.5e-05	0.000368	CcSEcCtD
Irbesartan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.5e-05	0.000367	CcSEcCtD
Irbesartan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.5e-05	0.000367	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.47e-05	0.00144	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.46e-05	0.000366	CcSEcCtD
Irbesartan—Pain—Lamivudine—acquired immunodeficiency syndrome	8.44e-05	0.000365	CcSEcCtD
Irbesartan—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.44e-05	0.000365	CcSEcCtD
Irbesartan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.34e-05	0.00036	CcSEcCtD
Irbesartan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.31e-05	0.000359	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	8.24e-05	0.0014	CbGpPWpGaD
Irbesartan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.23e-05	0.000355	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.22e-05	0.00139	CbGpPWpGaD
Irbesartan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	8.22e-05	0.000355	CcSEcCtD
Irbesartan—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.21e-05	0.000355	CcSEcCtD
Irbesartan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.18e-05	0.000354	CcSEcCtD
Irbesartan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.18e-05	0.000354	CcSEcCtD
Irbesartan—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.18e-05	0.000353	CcSEcCtD
Irbesartan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	8.13e-05	0.000352	CcSEcCtD
Irbesartan—Rash—Indinavir—acquired immunodeficiency syndrome	8.11e-05	0.00035	CcSEcCtD
Irbesartan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.1e-05	0.00035	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.08e-05	0.00137	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.08e-05	0.00137	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.07e-05	0.00137	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	8.07e-05	0.000349	CcSEcCtD
Irbesartan—Headache—Indinavir—acquired immunodeficiency syndrome	8.06e-05	0.000348	CcSEcCtD
Irbesartan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	8.03e-05	0.000347	CcSEcCtD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	8.01e-05	0.00136	CbGpPWpGaD
Irbesartan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.95e-05	0.000344	CcSEcCtD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	7.94e-05	0.00135	CbGpPWpGaD
Irbesartan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.92e-05	0.000342	CcSEcCtD
Irbesartan—JUN—Innate Immune System—CCR2—acquired immunodeficiency syndrome	7.91e-05	0.00134	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	7.86e-05	0.00133	CbGpPWpGaD
Irbesartan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000339	CcSEcCtD
Irbesartan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.8e-05	0.000337	CcSEcCtD
Irbesartan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.8e-05	0.000337	CcSEcCtD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	7.79e-05	0.00132	CbGpPWpGaD
Irbesartan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.73e-05	0.000334	CcSEcCtD
Irbesartan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.71e-05	0.000333	CcSEcCtD
Irbesartan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.69e-05	0.000332	CcSEcCtD
Irbesartan—Rash—Efavirenz—acquired immunodeficiency syndrome	7.66e-05	0.000331	CcSEcCtD
Irbesartan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.65e-05	0.000331	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	7.65e-05	0.0013	CbGpPWpGaD
Irbesartan—Nausea—Indinavir—acquired immunodeficiency syndrome	7.64e-05	0.00033	CcSEcCtD
Irbesartan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.62e-05	0.000329	CcSEcCtD
Irbesartan—Headache—Efavirenz—acquired immunodeficiency syndrome	7.61e-05	0.000329	CcSEcCtD
Irbesartan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.61e-05	0.000329	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	7.52e-05	0.00127	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	7.52e-05	0.00127	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.46e-05	0.00126	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.43e-05	0.00126	CbGpPWpGaD
Irbesartan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.42e-05	0.000321	CcSEcCtD
Irbesartan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.39e-05	0.000319	CcSEcCtD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	7.39e-05	0.00125	CbGpPWpGaD
Irbesartan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.36e-05	0.000318	CcSEcCtD
Irbesartan—Rash—Delavirdine—acquired immunodeficiency syndrome	7.33e-05	0.000317	CcSEcCtD
Irbesartan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.32e-05	0.000317	CcSEcCtD
Irbesartan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.32e-05	0.000316	CcSEcCtD
Irbesartan—Headache—Delavirdine—acquired immunodeficiency syndrome	7.28e-05	0.000315	CcSEcCtD
Irbesartan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	7.27e-05	0.000314	CcSEcCtD
Irbesartan—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.22e-05	0.000312	CcSEcCtD
Irbesartan—JUN—Immune System—ACTG1—acquired immunodeficiency syndrome	7.15e-05	0.00121	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.13e-05	0.00121	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.13e-05	0.00121	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	7.12e-05	0.00121	CbGpPWpGaD
Irbesartan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.11e-05	0.000307	CcSEcCtD
Irbesartan—JUN—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	7.09e-05	0.0012	CbGpPWpGaD
Irbesartan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.08e-05	0.000306	CcSEcCtD
Irbesartan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.08e-05	0.000306	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.99e-05	0.00118	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.99e-05	0.00118	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	6.98e-05	0.00118	CbGpPWpGaD
Irbesartan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.98e-05	0.000302	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	6.92e-05	0.00117	CbGpPWpGaD
Irbesartan—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.91e-05	0.000298	CcSEcCtD
Irbesartan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.84e-05	0.000296	CcSEcCtD
Irbesartan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.84e-05	0.000295	CcSEcCtD
Irbesartan—Rash—Ritonavir—acquired immunodeficiency syndrome	6.78e-05	0.000293	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.77e-05	0.00115	CbGpPWpGaD
Irbesartan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.77e-05	0.000293	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	6.76e-05	0.00115	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL6—acquired immunodeficiency syndrome	6.76e-05	0.00115	CbGpPWpGaD
Irbesartan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.75e-05	0.000292	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.75e-05	0.00114	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	6.74e-05	0.00114	CbGpPWpGaD
Irbesartan—Headache—Ritonavir—acquired immunodeficiency syndrome	6.73e-05	0.000291	CcSEcCtD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	6.7e-05	0.00114	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.67e-05	0.00113	CbGpPWpGaD
Irbesartan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.58e-05	0.000284	CcSEcCtD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.57e-05	0.00111	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	6.55e-05	0.00111	CbGpPWpGaD
Irbesartan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.53e-05	0.000282	CcSEcCtD
Irbesartan—Rash—Saquinavir—acquired immunodeficiency syndrome	6.52e-05	0.000282	CcSEcCtD
Irbesartan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.52e-05	0.000282	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.5e-05	0.0011	CbGpPWpGaD
Irbesartan—Headache—Saquinavir—acquired immunodeficiency syndrome	6.48e-05	0.00028	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.45e-05	0.00109	CbGpPWpGaD
Irbesartan—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.39e-05	0.000276	CcSEcCtD
Irbesartan—JUN—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	6.38e-05	0.00108	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.34e-05	0.00108	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.34e-05	0.00108	CbGpPWpGaD
Irbesartan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.28e-05	0.000271	CcSEcCtD
Irbesartan—Rash—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000269	CcSEcCtD
Irbesartan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000269	CcSEcCtD
Irbesartan—Headache—Lamivudine—acquired immunodeficiency syndrome	6.18e-05	0.000267	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.15e-05	0.00104	CbGpPWpGaD
Irbesartan—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.15e-05	0.000266	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	6.11e-05	0.00104	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.1e-05	0.00103	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.06e-05	0.00103	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	6e-05	0.00102	CbGpPWpGaD
Irbesartan—JUN—Immune System—MBL2—acquired immunodeficiency syndrome	5.87e-05	0.000996	CbGpPWpGaD
Irbesartan—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000253	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	5.75e-05	0.000976	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.62e-05	0.000952	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.61e-05	0.000952	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	5.57e-05	0.000944	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.54e-05	0.000939	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	5.44e-05	0.000922	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	5.4e-05	0.000916	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	5.36e-05	0.000909	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	5.34e-05	0.000906	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.33e-05	0.000904	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.33e-05	0.000904	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.31e-05	0.000901	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.24e-05	0.000887	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.19e-05	0.00088	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	5.1e-05	0.000865	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	5.09e-05	0.000862	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	5.09e-05	0.000862	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.08e-05	0.000861	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	4.95e-05	0.00084	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.93e-05	0.000835	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.83e-05	0.000818	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.82e-05	0.000817	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.79e-05	0.000812	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.78e-05	0.00081	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.78e-05	0.00081	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.75e-05	0.000806	CbGpPWpGaD
Irbesartan—JUN—Immune System—CCR2—acquired immunodeficiency syndrome	4.61e-05	0.000781	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	4.45e-05	0.000755	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.41e-05	0.000747	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.35e-05	0.000737	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL6—acquired immunodeficiency syndrome	4.28e-05	0.000726	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	4.23e-05	0.000717	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNA1—acquired immunodeficiency syndrome	4.15e-05	0.000703	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD79A—acquired immunodeficiency syndrome	4.03e-05	0.000682	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.02e-05	0.000682	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.99e-05	0.000676	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.75e-05	0.000635	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.75e-05	0.000635	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.63e-05	0.000616	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	3.6e-05	0.000609	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.58e-05	0.000607	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.53e-05	0.000598	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	3.47e-05	0.000588	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	3.44e-05	0.000583	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.29e-05	0.000558	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40LG—acquired immunodeficiency syndrome	3.28e-05	0.000556	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.27e-05	0.000555	CbGpPWpGaD
Irbesartan—JUN—Immune System—CSF2—acquired immunodeficiency syndrome	3.25e-05	0.00055	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD8A—acquired immunodeficiency syndrome	3.25e-05	0.00055	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	3.23e-05	0.000548	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.2e-05	0.000543	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.2e-05	0.000542	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-B—acquired immunodeficiency syndrome	3.12e-05	0.000529	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.98e-05	0.000505	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.95e-05	0.0005	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	2.94e-05	0.000499	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.93e-05	0.000496	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.85e-05	0.000483	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.81e-05	0.000476	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.8e-05	0.000475	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.8e-05	0.000475	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.77e-05	0.000469	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.57e-05	0.000435	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.56e-05	0.000435	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.51e-05	0.000426	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.5e-05	0.000424	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.27e-05	0.000385	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.13e-05	0.000361	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.1e-05	0.000356	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ALB—acquired immunodeficiency syndrome	2.03e-05	0.000344	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNG—acquired immunodeficiency syndrome	1.93e-05	0.000327	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.93e-05	0.000327	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.92e-05	0.000325	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.89e-05	0.000321	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.88e-05	0.000319	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—acquired immunodeficiency syndrome	1.86e-05	0.000316	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.73e-05	0.000293	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—acquired immunodeficiency syndrome	1.71e-05	0.000291	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.66e-05	0.000281	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.48e-05	0.000252	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.48e-05	0.00025	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.35e-05	0.000228	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.15e-05	0.000195	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	1.14e-05	0.000194	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000188	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000188	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—acquired immunodeficiency syndrome	1.01e-05	0.000171	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.72e-06	0.000148	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	7.37e-06	0.000125	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.52e-06	0.00011	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	6.05e-06	0.000103	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	6e-06	0.000102	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	5.13e-06	8.69e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.96e-06	6.71e-05	CbGpPWpGaD
